SCHEMBL7688880

SCHEMBL7688880

CCCNC(=O)c1ccc2c(Oc3ccc(C[C@@H](CO)N(Cc4ccccc4)C[C@@H](O)c4cccc(Cl)c4)cc3)ccnc2c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 3/20 0.39
AURKA O14965 2/20 0.39
TEK Q02763 2/20 0.39
LCK P06239 1/20 0.39
ADRB3 P13945 9/20 0.39
ADRB1 P08588 5/20 0.39
CYP2D6 P10635 3/20 0.36
CYP2C9 P11712 3/20 0.36
CYP2C19 P33261 3/20 0.36
ADRB2 P07550 1/20 0.36
ADRA1D P25100 1/20 0.36
ADRA1A P35348 1/20 0.36
ADRA1B P35368 1/20 0.36
CYP1A2 P05177 1/20 0.36
USP7 Q93009 1/20 0.36
KDM4E B2RXH2 2/20 0.35
ALDH1A1 P00352 2/20 0.35
CYP3A4 P08684 2/20 0.35
HPGD P15428 2/20 0.35
MET P08581 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7688878 1.00 KDR (0.39) KDRAURKATEKLCKADRB3
SCHEMBL7688932 0.95 ADRB3 (0.39) KDRAURKATEKLCKADRB3
SCHEMBL7688930 0.95 ADRB3 (0.39) KDRAURKATEKLCKADRB3
SCHEMBL7693305 0.94 KDR (0.42) KDRAURKATEKLCKADRB3
SCHEMBL7693306 0.94 KDR (0.42) KDRAURKATEKLCKADRB3
SCHEMBL7692428 0.93 ADRB3 (0.37) KDRAURKATEKLCKADRB3
SCHEMBL7687573 0.91 ADRB3 (0.36) KDRADRB3ADRB1CYP2D6CYP2C9
SCHEMBL7687570 0.91 ADRB3 (0.36) KDRADRB3ADRB1CYP2D6CYP2C9
SCHEMBL7694151 0.90 ADRB3 (0.37) KDRADRB3ADRB1CYP2D6CYP2C9
SCHEMBL7694153 0.90 ADRB3 (0.37) KDRADRB3ADRB1CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2002000622-A2 AMINOALCOHOL DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-01-03 WO disclosed